T-cell immunotherapies
Jan 25, 2018
Business Cocktail
Pharma startup Bonti has recently grabbed a funding of USD 15 million Managed by Ex-Allergan executives biotech startup Bonti has recently bagged a funding of USD 15.5 million in series C, The Company is focused on developing a new botulinum neurotoxin for both therapeutic and cosmetic uses. Funding will help in the...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
